Bioequivalence
Conditions
Keywords
COVID-19 drug treatment, Antiviral Agents, Favipiravir, Novagenix, Farmagen
Brief summary
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.
Detailed description
Favipiravir is a drug with a mechanism of action different from that of the existing influenza antiviral drugs and effective against all types and sub-types of human influenza A, B and C viruses in vitro, showing anti-viral activity against various influenza virus strains including avian and swine viruses. Favipiravir also has shown anti-viral activity even against amantadine, oseltamivir and zanamivir-resistant influenza viruses in vitro. The mechanism of action of favipiravir is the selective inhibition of RNA polymerase by favipiravir ribosyl triphosphate formed by cellular enzymes in the influenza virus leading to antiviral activity.
Interventions
DRUGFAVICOVIR 200 mg Film Tablet
FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
Sponsors
Novagenix Bioanalytical Drug R&D Center
Farmagen Ar-Ge Biyot. Ltd. Sti
Atabay Kimya Sanayi Ticaret A.S.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy Caucasian male subjects aged between 20 and 40 years 2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during the study period 3. Two Negative Covid-19 PCR test results 4. Negative alcohol breath test results 5. Normal physical examination at screening visit 6. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age 7. Ability to communicate adequately with the investigator himself or his representatives 8. Ability and agreement to comply with the study requirements 9. Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm 10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest 11. Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium, calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate) 12. Understanding of the study and agreement to give a written informed consent according to section 20.3 13. Understanding of that he and his partner will use a practice adequate contraception during the study and at least 7 days after the study 14. Volunteer's compliance with isolation rules defined at study protocol
Exclusion criteria
1. Who have atopic constitution or asthma or known allergy for favipiravir and/or any other ingredients of the products. 2. Any history or presence of clinical relevance of cardiovascular, neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria. 3. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator), 4. Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy. 5. Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration. 6. Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement. 7. Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product). 8. Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication. 9. History of allergic response to heparin. 10. Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug. 11. Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day. 12. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study. 13. History of drug abuse. 14. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits). 15. Positive blood test for HBV, HCV and HIV. 16. Who have relationship to the investigator. 17. Who are not suitable to any of inclusion criteria. 18. History of difficulty of swallowing. 19. Intake of depot injectable solutions (including study medications) within 6 months before start of the study. 20. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study. 21. Special diet due to any reason, e.g. vegetarian.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-tlast of Favipiravir | 0 to 24 hours post-dose | Area under the concentration-time curve of favipiravir in plasma over the time interval from 0 to 24 hours |
| Cmax of Favipiravir | 0 to 24 hours post-dose | Maximum plasma concentration of favipiravir |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-inf of Favipiravir | 0 to 24 hours post-dose | Area under the plasma concentration curve to infinite time of favipiravir |
| Tmax of Favipiravir | 0 to 24 hours post-dose | Time to reach maximum plasma concentration of favipiravir |
Countries
Turkey (Türkiye)
Participant flow
Pre-assignment details
57 subject screened
Participants by arm
| Arm | Count |
|---|---|
| FAVICOVIR Then AVIGAN Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. | 15 |
| AVIGAN Then FAVICOVIR Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state. | 15 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Period 1 | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | FAVICOVIR Then AVIGAN | AVIGAN Then FAVICOVIR | Total |
|---|---|---|---|
| Age, Continuous | 29 years | 29 years | 29 years |
| Race/Ethnicity, Customized Caucasian | 15 subjects | 15 subjects | 30 subjects |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 15 Participants | 15 Participants | 30 Participants |
| Sex/Gender, Customized Male | 15 Participants | 15 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 29 | 0 / 29 |
| other Total, other adverse events | 0 / 29 | 0 / 29 |
| serious Total, serious adverse events | 0 / 29 | 0 / 29 |
Outcome results
Primary
AUC0-tlast of Favipiravir
Area under the concentration-time curve of favipiravir in plasma over the time interval from 0 to 24 hours
Time frame: 0 to 24 hours post-dose
Population: 29 subjects were analysed and included in statistical analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Favicovir 200 mg FT | AUC0-tlast of Favipiravir | 9641.989 ng*hr/mL | Standard Deviation 2545.1 |
| Avigan 200 mg FT | AUC0-tlast of Favipiravir | 9907.170 ng*hr/mL | Standard Deviation 2423.5 |
p-value: 090% CI: [0.94, 0.9977]ANOVA
Primary
Cmax of Favipiravir
Maximum plasma concentration of favipiravir
Time frame: 0 to 24 hours post-dose
Population: 29 subjects were analysed and included in statistical analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Favicovir 200 mg FT | Cmax of Favipiravir | 5411.624 ng/mL | Standard Deviation 2025.6 |
| Avigan 200 mg FT | Cmax of Favipiravir | 5002.171 ng/mL | Standard Deviation 1231.1 |
p-value: 0.015590% CI: [0.9292, 1.1989]ANOVA
Secondary
AUC0-inf of Favipiravir
Area under the plasma concentration curve to infinite time of favipiravir
Time frame: 0 to 24 hours post-dose
Population: 29 subjects were analysed and included in statistical analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Favicovir 200 mg FT | AUC0-inf of Favipiravir | 9910.494 ng*hr/mL | Standard Deviation 2618.9 |
| Avigan 200 mg FT | AUC0-inf of Favipiravir | 10152.115 ng*hr/mL | Standard Deviation 2507.694 |
p-value: 090% CI: [0.944, 1.0006]ANOVA
Secondary
Tmax of Favipiravir
Time to reach maximum plasma concentration of favipiravir
Time frame: 0 to 24 hours post-dose
Population: 29 subjects were analysed and included in statistical analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Favicovir 200 mg FT | Tmax of Favipiravir | 0.609 hr | Standard Deviation 0.343 |
| Avigan 200 mg FT | Tmax of Favipiravir | 0.733 hr | Standard Deviation 0.478 |